Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niacin ER/Lovastatin in Intermittent Claudication
NCT00062556Phase 3Completed
- Sponsor
- Kos Pharmaceuticals, Inc.
- Start
- Jan 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of niacin extended-release + lovastatin in intermittent claudication (IC) (3 arms), sponsored by Kos Pharmaceuticals, Inc. Primary endpoints: Peak Walking Time at 28 weeks and Claudication Onset Time at 28 weeks. Started Jan 2003; status: completed.
02
Drugs
niacin extended-release + lovastatin
03
Conditions
intermittent claudication (IC)
Beyond the preview
Go deeper on NCT00062556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062556.